阿尔马尔与波依定治疗高血压病的疗效比较

Comparative Efficacy of Almarl versus Plendil in the Treatment of Patients with Essential Hypertention

    摘要
  • 摘要: 目的　观察比较阿尔马尔和波依定治疗原发性高血压病的临床疗效和安全性。方法　本试验采用平行、对照、开放的方法 ,选取门诊和住院成年高血压患者 6 3例 ,年龄 36～ 6 9岁 ,舒张压 (DBP)在 90～ 110mmHg之间。选取符合条件者随即录入阿尔马尔组 5～ 10mgbid ,或波依定组 5～ 10mgbid ,治疗 8周 ,观察降压效果、副作用、QT离散度 (QTd)、生化指标的改变。结果　对轻、中度高血压者以每日 10～ 2 0mg的阿尔马尔治疗 8周后 ,SBP可由 15 7± 6降至 139± 6mmHg ,DBP由 10 1± 3降至 84± 4mmHg。总有效率分别为 77.4 %、87.1%。阿尔马尔对血压、心率、QTd的降低均明显优于波依定 (P <0 0 1)。结论　与波依定组相比 ,阿尔马尔不仅降压上有明显疗效 ,而且有较好的安全性和耐受性。

     

    Abstract: Aim To determine the antihypertensive effects and tolerance of the Almarl （Arotinolol hydrochloride） and Plendil. Methods Sixty three patient aged from 36 to 69 years old with hypertension（DBP=90～110 mmHg） were enrolled. They were randomized to receive Almarl 5 to 10 mg bid or Plendil 5 to 10mg bid for 8 weeks. Changes in blood pressure, side effects, QT dispersion and biochemical examination were evaluated. Result Almarl 10 to 20 mg/d reduced SBP from 157±6 to 139±6 mmHg and DBP from 100±3 to 84±4 mmHg in mild and moderate hypertension. The total response rate was 77.4% and 87.1%.\ The blood pressure, QT dispersion and heart rate were significantly improved by Almarl than by Plendil （ P ＜0 01）. Conclusion Compared with the Plendil, Almarl is not only effective in lowering blood pressure, but also safe and well tolerated.

     

    • HTML全文
    • 参考文献(3)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回